Oxford BioDynamicsSTU:LMQ EBITDA Margin % is -958.29% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 91.67% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oxford BioDynamics's EBITDA for the
six
months ended in Sep. 2025 was €-5.61 Mil. Oxford BioDynamics's Revenue for the
six
months ended in Sep. 2025 was €0.59 Mil. Therefore, Oxford BioDynamics's EBITDA margin for the quarter that ended in Sep. 2025 was -958.29%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oxford BioDynamics EBITDA Margin % Related Terms
Oxford BioDynamics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LMQ vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioDynamics (STU:LMQ) has a EBITDA Margin % of -958.29% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #187 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 91.7%.
Is Oxford BioDynamics' EBITDA Margin % too high?
Oxford BioDynamics' current EBITDA Margin % is -958.29%. Based on the distribution chart, Oxford BioDynamics ranks #187 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #187 out of 204 companies for EBITDA Margin %. This places Oxford BioDynamics in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford BioDynamics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioDynamics's current EBITDA Margin % is -958.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (STU:LMQ) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 95% below its estimated fair value. The current EBITDA Margin % is -958.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oxford BioDynamics (STU:LMQ), the current EBITDA Margin % is -958.29% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LMQ has been successfully added to your 